Candel Therapeutics Inc. (CADL)
Market Closed
17 Apr, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
4. 57
-0.38
-7.68%
$
157.18M Market Cap
- P/E Ratio
0% Div Yield
534,500 Volume
-0.91 Eps
$ 4.95
Previous Close Day Range
4.5 4.78
Year Range
3.79 14.6
Summary
CADL closed Thursday lower at $4.57, a decrease of 7.68% from Wednesday's close, completing a monthly decrease of -18.54% or $1.04. Over the past 12 months, CADL stock lost -46.61%.
CADL is not paying dividends to its shareholders.
The last earnings report, released on Mar 14, 2025, missed the consensus estimates by -0.4%. On average, the company has fell short of earnings expectations by -0.49%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).
Want to track CADL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CADL Chart
Candel Therapeutics Inc. Dividends
CADL is not paying dividends to its shareholders.
Candel Therapeutics Inc. Earnings
| 14 Mar 2025 Date | | - Cons. EPS | - EPS |
| 14 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Sep 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 28 Mar 2024 Date | | - Cons. EPS | - EPS |
CADL is not paying dividends to its shareholders.
| 14 Mar 2025 Date | | - Cons. EPS | - EPS |
| 14 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Sep 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 28 Mar 2024 Date | | - Cons. EPS | - EPS |
Candel Therapeutics Inc. (CADL) FAQ
What is the stock price today?
The current price is $4.57.
On which exchange is it traded?
Candel Therapeutics Inc. is listed on NASDAQ (NMS).
What is its stock symbol?
The ticker symbol is CADL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 157.18M.
Has Candel Therapeutics Inc. ever had a stock split?
No, there has never been a stock split.
Candel Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. CEO | NASDAQ (NMS) Exchange | US1374041093 ISIN |
| United States Country | 42 Employees | - Last Dividend | - Last Split | 27 Jul 2021 IPO Date |
Overview
Candel Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company rooted in the discovery and development of novel immunotherapies aimed at treating cancer patients. With a focus on leveraging innovative technologies and scientific advances, Candel Therapeutics is committed to achieving breakthroughs in cancer treatment. Since its inception in 2003 under the name Advantagene, Inc., the company has undergone a significant evolution, culminating in a name change to Candel Therapeutics, Inc. in November 2020. Headquartered in Needham, Massachusetts, the organization continues to push the boundaries of cancer therapy with its diverse pipeline of drug candidates and proprietary discovery platforms.
Products and Services
- CAN-2409
- CAN-3110
- enLIGHTEN Discovery Platform
Contact Information
Address: 117 Kendrick Street
Phone: 617 916 5445
Website: https://www.candeltx.com
2025 © Marketlog. All Rights Reserved.
